- Conditions
- Advanced Solid Tumor
- Interventions
- BNT326, Itraconazole, Paroxetine, Pumitamig
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 3,304
matching trials from the local directory fallback.
- Conditions
- Type 2 Diabetes
- Interventions
- LY3457263, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Santa Ana, California • Ocala, Florida + 21 more
- Conditions
- Obesity and Overweight
- Interventions
- Diet containing 20% ultra processed foods, Diet containing 80% ultra processed foods
- Behavioral
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Recurrent Pericarditis
- Interventions
- VTX2735
- Drug
- Lead sponsor
- Zomagen Biosciences Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- La Jolla, California • Orange, California • Saint Augustine, Florida + 10 more
- Conditions
- Idiopathic Hypersomnia, Narcolepsy Type 1, Narcolepsy Type 2
- Interventions
- ALKS 2680, 10mg, ALKS 2680, 14mg, ALKS 2680, 18mg, ALKS 2680, 4mg, ALKS 2680, 6mg, ALKS 2680, 8mg
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 786 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 34
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Abemaciclib, Atezolizumab, Atirmociclib, Bevacizumab, Capecitabine, Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Empagliflozin, Fulvestrant, Giredestrant, Inavolisib (Dose #1), Inavolisib (Dose #2), Ipatasertib, Letrozole, Metformin, Nab-Paclitaxel, Palbociclib, Ribociclib (Dose #1), Ribociclib (Dose #2), SGN-LIV1A, Sacituzumab Govitecan, Selicrelumab, Tocilizumab, Trastuzumab Deruxtecan
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 26
- States / cities
- Duarte, California • Irvine, California • La Jolla, California + 20 more
- Conditions
- Obesity, Overweight
- Interventions
- LY4329090, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 184 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Daytona Beach, Florida • Dallas, Texas
- Conditions
- AML (Acute Myeloid Leukemia)
- Interventions
- CHM-029
- Drug
- Lead sponsor
- Charm Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Duarte, California • New Haven, Connecticut • Grand Rapids, Michigan
- Conditions
- Castration-Resistant Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC), Prostate Cancer, Prostate Cancer (Adenocarcinoma)
- Interventions
- Apalutamide, Oral MRT-2359
- Drug
- Lead sponsor
- Monte Rosa Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Newport Beach, California • Colorado Springs, Colorado + 11 more
- Conditions
- CNS Metastases, Central Nervous System Metastasis, Recurrent Medulloblastoma, Refractory Medulloblastoma
- Interventions
- 25 mCi 177Lu- DTPA-omburtamab
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 3 Years to 22 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- B-cell Non Hodgkin Lymphoma
- Interventions
- ARC-02, Rituximab
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Louisville, Kentucky • New York, New York + 4 more
- Conditions
- Gastric Cancer, Metastatic
- Interventions
- Cyclophosphamide, Fludarabine, Rimiducid (AP1903), TGFBR2 KO CAR27/IL-15 NK cells
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer (NSCLC), Lung Disease, Lung Neoplasms, Non-Small Cell Lung Cancer, Non-Small-Cell Lung, Non-small Cell Lung Cancer, Non-squamous, Non-small Cell Lung Cancer, Squamous
- Interventions
- Chemotherapy Regimen 1, Chemotherapy Regimen 2, PF-08634404
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 15
- States / cities
- Huntsville, Alabama • Stanford, California • Athens, Georgia + 7 more
- Conditions
- Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
- Interventions
- LY4268989, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,431 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 46 more
- Conditions
- Breast Cancer
- Interventions
- CLR 125, Iopofosine I 131
- Drug
- Lead sponsor
- Cellectar Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Glen Burnie, Maryland • Rochester, Minnesota + 1 more
- Conditions
- Breast Neoplasms
- Interventions
- Goserelin, Imlunestrant, Tamoxifen 20 mg
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 27 more
- Conditions
- Advanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer, Metastatic Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer
- Interventions
- Chemotherapy Regimen 1, Chemotherapy Regimen 2, PF-08634404, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 226
- States / cities
- Bullhead City, Arizona • Chandler, Arizona • Gilbert, Arizona + 164 more
- Conditions
- Ulcerative Colitis
- Interventions
- LY4268989, LY4268989 Placebo, Mirikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 40
- States / cities
- Scottsdale, Arizona • Anaheim, California • Lancaster, California + 36 more
- Conditions
- Drug-Related Side Effects and Adverse Reactions, Nausea, Neoplasms, Vomiting
- Interventions
- Background Chemotherapy, LY3537021, Placebo, Standard of Care Antiemetic Therapies
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Greenbrae, California • Irvine, California • Los Alamitos, California + 17 more
- Conditions
- B-cell Lymphoma, Lymphoma, B-cell Marginal Zone, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle Cell, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia
- Interventions
- LY4152199 - IV
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 23
- States / cities
- Duarte, California • Aurora, Colorado • Denver, Colorado + 17 more
- Conditions
- Acute Myeloid Leukaemia (AML), Acute Myeloid Leukemia (AML)
- Interventions
- 5hmC Biomarker, Anthracycline, Azacitidine (AZA), Cytarabine (Ara-C), Decitabine 20 mg/m²/day for 5 days, Venetoclax
- Diagnostic Test · Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pancreatic Cyst, Pancreatic Mucinous Cystic Neoplasm
- Interventions
- Tamoxifen 20mg
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Migraine
- Interventions
- RELAXaHEAD Smartphone App Version 1, RELAXaHEAD Smartphone App Version 2
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- AZD0120
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 31 more